Countdown to 2030: eliminating hepatitis B disease, China

Jue Liu, Wannian Liang, Wenzhan Jing, Min Liu, Jue Liu, Wannian Liang, Wenzhan Jing, Min Liu

Abstract

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. The country has made good progress in reducing incidence of HBV infection in the past three decades. The achievements are mainly due to high vaccination coverages among children and high coverage of timely birth-dose vaccine for prevention of mother-to-child transmission of HBV (both > 95%). However, China still faces challenges in achieving its target of 65% reduction in mortality from hepatitis B by 2030. Based on targets of the World Health Organization's Global health sector strategy on viral hepatitis 2016-2021, we highlight further priorities for action towards HBV elimination in China. To achieve the impact target of reduced mortality we suggest that the service coverage targets of diagnosis and treatment should be prioritized. First, improvements are needed in the diagnostic and treatment abilities of medical institutions and health workers. Second, the government needs to reduce the financial burden of health care on patients. Third, better coordination is needed across existing national programmes and resources to establish an integrated prevention and control system that covers prevention, screening, diagnosis and treatment of HBV infection across the life cycle. In this way, progress can be made towards achieving the target of eliminating hepatitis B in China by 2030.

Figures

Fig. 1
Fig. 1
WHO evaluation framework for hepatitis B virus elimination
Fig. 2
Fig. 2
Target and actual hepatitis B virus vaccination coverage and hospital delivery rate in China, 1992–2015
Fig. 3
Fig. 3
Mortality due to hepatitis B disease in China and globally, 1990–2016
Fig. 4
Fig. 4
Disability-adjusted life-years attributed to hepatitis B disease in China and globally, 1990–2016

References

    1. Global hepatitis report 2017. Geneva: World Health Organization; 2017. Available from: [cited 2018 Mar 20].
    1. Fact-sheet: hepatitis B [internet]. Geneva: World Health Organization; 2018. Available from: [cited 2018 Jul 18].
    1. Global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization; 2016. Available from: [cited 2018 Mar 29].
    1. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Technical report. Geneva: World Health Organization; 2016. Available from: [cited 2018 Mar 15].
    1. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014. December;60(6):2099–108. 10.1002/hep.27406
    1. Global health data results tool [internet]. Seattle: Institute for Health Metrics and Evaluation; 2018. Available from: [cited 2018 Apr 20].
    1. Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016. January;16(1):80–6. 10.1016/S1473-3099(15)00218-2
    1. Cui F, Shen L, Li L, Wang H, Wang F, Bi S, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017. May;23(5):765–72. 10.3201/eid2305.161477
    1. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009. November 5;27(47):6550–7. 10.1016/j.vaccine.2009.08.048
    1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, et al.; Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018. June;3(6):383–403. 10.1016/S2468-1253(18)30056-6
    1. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Available from: [cited 2018 Mar 20].
    1. [National viral hepatitis prevention and control plan (2017–2020).] Beijing: Department of Disease Prevention and Control, National Health Commission of the People's Republic of China; 2017. Chinese. Available from: [cited 2018 Apr 30].
    1. National Health Commission of the People’s Republic of China. The 2017 China health statistics yearbook. Beijing: China Union Medical University Press; 2017.
    1. [Notice on launching the pilot project of the national free preconception health examination project.] Beijing: National Health Commission of the People's Republic of China; 2010. Chinese. Available from: [cited 2018 Mar 29].
    1. Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, et al. Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: an observational study. J Viral Hepat. 2017. August;24(8):679–86. 10.1111/jvh.12693
    1. [2016 China health and family planning development statistics bulletin.] Beijing: National Health Commission of the People’s Republic of China; 2017. Chinese. Available from: [cited 2018 Mar 29].
    1. [Reply to recommendation 4781 of the fourth session of the 12th National People's Congress.] Beijing: National Health Commission of the People’s Republic of China; 2016. Chinese. Available from: [cited 2018 Mar 25].
    1. Zhang SX, Dang RB, Zhang WD, Liang XF, Cui FQ. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008. October;29(10):1003–8. [Chinese.]
    1. [Newsletter on supervision and inspection of vaccine circulation and vaccination management regulations.] Beijing: National Health Commission of the People's Republic of China; 2015. Chinese. Available from: [cited 2018 Mar 20].
    1. [China has achieved remarkable results in controlling hepatitis B.] Beijing: Department of Disease Prevention and Control, National Health Commission of the People's Republic of China; 2013. Chinese. Available from: [cited 2018 Mar 8].
    1. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009. July 1;200(1):39–47. 10.1086/599332
    1. Cui J, Cao L, Zheng J, Cao L, Duo M, Xiao Q. Reported coverage of vaccines in the national immunization program of China, 2015. Chin J Vacc Imm. 2017 06:601–7. Available from: [cited 2018 Nov 28].
    1. Cui J, Cao L, Zheng J, Cao L, Yuan P, Wang M, et al. Analysis of reported coverage rates of vaccines in national immunization program in China, 2014. Chin J Vacc Imm. 2016 01:34-40. Available from: [cited 2019 Jan 16].
    1. Cui J, Cao L, Zheng J, Cao L, Yuan P, Li L. Coverage analysis of national immunization program vaccines reported in China, 2013. Chin J Vacc Imm. 2015 03: 289-94. Available from: [cited 2019 Jan 16].
    1. Xu Y, Liu H, Wang Y, Hao R, Li Z, Song H. The next step in controlling HBV in China. BMJ. 2013. July 16;347 jul16 1:f4503. 10.1136/bmj.f4503
    1. [Prevention of mother-to-child transmission for human immunodeficiency virus: syphilis and hepatitis B virus work plan.] Beijing: National Health Commission of the People's Republic of China; 2011. Chinese. Available from: [cited 2018 Mar 28].
    1. Wang AL, Qiao YP, Wang LH, Fang LW, Wang F, Jin X, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ. 2015. January 1;93(1):52–6. 10.2471/BLT.14.139626
    1. [Yuhang becomes a national pilot area to eliminate of mother-to-child transmission for HIV, syphilis and hepatitis B virus project.] [internet]. Zhejiang: Government of Yuhang Province; 2017. Chinese. Available from: [cited 2018 Apr 29].
    1. [Disposable sterile medical device supervision and management methods.] Beijing: National Health Commission of the People's Republic of China; 2000. Chinese. Available from: [cited 2018 Mar 8].
    1. Healthy China: deepening health reform in China building high-quality and value-based service delivery. Beijing; World Bank Group, World Health Organization, Ministry of Finance, National Health and Family Planning Commission, Ministry of Human Resources and Social Security, The People’s Republic of China; 2016.
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017. December;5(12):e1192–207. 10.1016/S2214-109X(17)30375-3
    1. [Specifications on nosocomial infection management.] Beijing: National Health Commission of the People's Republic of China; 2000. Chinese. Available from: [cited 2018 Mar 8].
    1. Wu Z, Cui F, Chen Y, Miao N, Gong X, Luo H, et al. Evaluation of immunization injection safety in China, 2010: achievements, future sustainability. Vaccine. 2013. December 27;31 Suppl 9:J43–8. 10.1016/j.vaccine.2012.11.057
    1. 2015 China AIDS response progress report. Beijing: National Health Commission of the People's Republic of China; 2015. Available from: [cited 2018 Mar 20].
    1. Country factsheets: China 2016 [internet]. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. Available from: [cited 2018 Mar 25].
    1. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al.; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017. December 28;5(4):297–318. 10.14218/JCTH.2016.00019
    1. Kong Y, Wei L, Hou J, Duan Z, Zhuang H, You H, et al. Demographic and baseline characteristics of patients in China registry of hepatitis B (CR-HEPB). Trials. 2017;18 Suppl 1:200.
    1. [National basic medical insurance, industrial injury insurance and maternity insurance reimbursement list. 2017 edition.] Beijing: Ministry of Human Resources and Social Security of the People's Republic of China; 2017. Chinese. Available from: [cited 2018 Mar 29].
    1. Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int. 2018. February;38 Suppl 1:115–21. 10.1111/liv.13640
    1. Shan S, Jia J. [Advances and challenge in prevention and treatment of hepatitis B in China.] Zhongguo Bingdubing Zazhi. 2017;01:5–8. Chinese. Available from [cited 2018 Nov 28].
    1. Wong WCW, Lo YR, Jiang S, Peng M, Zhu S, Kidd MR, et al. Improving the hepatitis cascade: assessing hepatitis testing and its management in primary health care in China. Fam Pract. 2018. December 12;35(6):731–7. 10.1093/fampra/cmy032
    1. Fu W, Zhao S, Zhang Y, Chai P, Goss J. Research in health policy making in China: out-of-pocket payments in Healthy China 2030. BMJ. 2018. February 5;360:k234. 10.1136/bmj.k234
    1. [Notice on the issuance of the national essential drugs list. 2018 edition.] Beijing: National Health Commission of the People's Republic of China; 2018. Chinese. Available from: [cited 2018 Oct 25].
    1. Vellozzi C, Averhoff F. An opportunity for further control of hepatitis B in China? Lancet Infect Dis. 2016. January;16(1):10–1. 10.1016/S1473-3099(15)00245-5
    1. Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int. 2016. November;36(11):1595–603. 10.1111/liv.13168
    1. Chen Y, Xie C, Zhang Y, Li Y, Ehrhardt S, Thio CL, et al. Knowledge regarding hepatitis B mother-to-child transmission among healthcare workers in South China. J Viral Hepat. 2018. May;25(5):561–70. 10.1111/jvh.12839
    1. Allain JP, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol. 2016. November;13(11):643–53. 10.1038/nrgastro.2016.138

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever